Glioblastoma multiforme (GBM) is an aggressive brain tumor with high mortality rates. Due to
its invasiveness, heterogeneity, and incomplete resection, the treatment is very challenging …

The receptor tyrosine kinase MERTK is aberrantly expressed in numerous human
malignancies, and is a novel target in cancer therapeutics. Physiologic roles of MERTK …

Personalized cancer treatments using combinations of drugs with a synergistic effect is
attractive but proves to be highly challenging. Here we present an approach to uncover the …

Existing three-dimensional (3D) culture techniques are limited by trade-offs between
throughput, capacity for high-resolution imaging in living state, and geometric control. Here …

Background Mesenchymal Consensus Molecular Subtype 4 (CMS4) colon cancer is
associated with poor prognosis and therapy resistance. In this proof-of-concept study, we …

Glioblastoma (GBM) is a lethal brain tumor with dismal prognosis. Current therapeutic
options, consisting of surgery, chemotherapy and radiation, have only served to marginally …

An interaction between ribosomal protein S3 (rpS3) and nuclear factor kappa B or
macrophage migration inhibitory factor in non-small-cell lung cancer is responsible for …

Purpose: Glioblastoma (GBM) is the most common and most lethal primary malignant brain
tumor. The receptor tyrosine kinase MET is frequently upregulated or overactivated in GBM …

Hormone-dependent breast cancer is the most abundant molecular subtype of the disease.
Despite the availability of endocrine treatments, the use of these drugs is limited by their …

Glioblastoma (GBM) is a highly aggressive form of brain cancer with a poor prognosis and
limited treatment options. The ALK and c-MET inhibitor Crizotinib has demonstrated …